Latest news

• FDA approves Alexion’s Ultomiris for generalised myasthenia gravis

  The drug is recommended for use for adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which accounts for 80% of people living with the ... Samantha Masterson, CEO, Myasthenia Gravis

• Alexion eyes Soliris combo with $930m deal to buy Achillion

  in 2018, thanks to new indications such as generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) that have broadened its reach.

• Amgen takes aim at Alexion’s patents for Soliris

  Alexion is expecting Soliris to make around $4.1bn in sales this year, up from $3.56bn in 2018, thanks in part to  new indications such as generalised myasthenia gravis (gMG)

• Alexion's Soliris adds new approval in rare disease NMOSD

  Soliris’ revenues hit $3.56bn last year, up 13% as Alexion added Generalised Myasthenia Gravis (gMG) to its two main indications, paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS).

• Germany will be first EU launch market for new Soliris indication

  Soliris was given the green light by the European Commission to treat adults with generalised myasthenia gravis (gMG), who are anti-acetylcholine receptor antibody-positive. ... While most symptoms in gMG - a chronic and progressive autoimmune disease -